Back to Search
LUIS FAYAD, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1205921095IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
J7482(TX)
Education
OTHER
Class of 1985
Research & Publications (20)
Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed.
PMID 17454622·Leuk Lymphoma·2007
8-other
Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
PMID 18284717·Clin Lymphoma Myeloma·2007
8-other
Novel treatment strategies for aggressive non-Hodgkin's lymphoma.
PMID 16556089·Expert Opin Pharmacother·2006
6-review
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome.
PMID 11133769·Blood·2001
4-observational
Functional joint imaging using 256-MDCT: Technical feasibility.
PMID 19457792·AJR Am J Roentgenol·2009
8-other
Mycobacterium tuberculosis infection: a rare late complication after cord blood hematopoietic SCT.
PMID 19029968·Bone Marrow Transplant·2009
5-case
Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.
PMID 19593328·Mod Pathol·2009
4-observational
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
PMID 19150940·Ann Oncol·2009
8-other
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
PMID 19451441·J Clin Oncol·2009
3-trial
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
PMID 18764869·Br J Haematol·2008
3-trial
Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD.
PMID 18779406·Blood·2008
8-other
Symptomatic anterior sternoclavicular joint secondary to a bicipital rib.
PMID 18926199·J Pediatr Surg·2008
5-case
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
PMID 18223284·Haematologica·2008
3-trial
Venous malformations: MR imaging features that predict skin burns after percutaneous alcohol embolization procedures.
PMID 18581111·Skeletal Radiol·2008
3-trial
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
PMID 18973182·Cancer·2008
3-trial
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
PMID 18411419·Blood·2008
3-trial
Low-grade intramedullary osteosarcoma of the tibia presenting as an intracortical lesion.
PMID 19292367·Orthopedics·2008
5-case
[High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma].
PMID 18221676·Med Clin (Barc)·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1205921095
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 41
- Publications
- 20
Are you this provider?
Claim Your Profile